NEW YORK (GenomeWeb) – VolitionRx today announced a collaboration with ImmuneHealth on a pilot study to asses the feasibility of VolitionRx’s technology for detecting prostate cancer. 

In the study, which was initiated today, ImmuneHealth, a Belgian contract research organization, will use VolitionRx’s NuQ assays to analyze 120 blood samples from patients across four Belgian hospitals. Four groups of patients will assessed — those with aggressive prostate cancer; those with indolent prostate cancer; those with prostate hyperplasia; and negative controls. 

ProstateCancer – Google News


Leave a Reply

Your email address will not be published. Required fields are marked *